NCT05345444Active, not recruiting
Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity. Ultimately, RTIRE may provide optimal treatment for intermediate risk prostate cancer patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 19 Apr 2022
- Start date
- 26 May 2022
- Primary completion date
- 24 Apr 2026
- Lead sponsor
- Weill Medical College of Cornell University
- Diseases
- Prostate cancer
- NCT number
- NCT05345444
What you commit to
- Study type: Interventional
- Participants enrolled: 48
- From 26 May 2022 to the primary completion date, 24 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior history of focal therapy.
- Prior history of receiving pelvic radiotherapy.
- Patients with a prior or concurrent disease whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the Principal Investigator.
Other illness
- Patient with metastatic prostate cancer.
- Patient with history of inflammatory bowel disease.
- History of bladder neck or urethral stricture.
Other
- Inability to undergo general anesthesia
- Inability to be placed within the lithotomy position for a transperineal approach to both biopsy and treatment.
Who the study is looking for
- Men aged ≥ 18
- ECOG 0 - 1
- Histologically confirmed intermediate risk prostate cancer per NCCN guidelines.
- Focal grade group 2 or 3 (GS 3+4 or GS 4 + 3) cancer in MRI target
- Gland size \< 80 cc
- Ability to undergo IRE
- Ability to receive MRI-guided radiotherapy.
- Ability to complete the HRQOL assessment surveys
- Willingness to undergo 12 month follow up biopsy
Age in the registry: 18 years to 99 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Weill Cornell Medicine Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.